CDKN2A and familial pancreatic carcinoma: In fact, the development of pancreatic cancer is marked by several genetic aberrations such as KRAS mutation and amplification, cyclin-dependent kinase inhibitor 2A (CDKN2A) silencing or loss of heterozygosity as well as mutation or loss of tumor protein 53 (TP53) and deletion of SMAD family member 4 (SMAD4) [13,14,15].